Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

C&EN 中文版

艾伯维(AbbVie)即将以630亿美元收购艾尔建(Allergan)

随着艾伯维(AbbVie)的药物Humira的专利到期,最新的药物行业巨头合并也会随之而来

by Lisa M. Jarvis
July 1, 2019 | A version of this story appeared in Volume 97, Issue 26

Article:

This article has been sent to the following recipient: